NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 383 filers reported holding NEKTAR THERAPEUTICS in Q2 2018. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,269 | -90.3% | 20,600 | -88.7% | 0.00% | – |
| Q1 2023 | $127,110 | -70.1% | 181,585 | -3.5% | 0.00% | -100.0% |
| Q4 2022 | $425,298 | -30.0% | 188,185 | -0.9% | 0.00% | 0.0% |
| Q3 2022 | $608,000 | -16.9% | 189,985 | -1.3% | 0.00% | 0.0% |
| Q2 2022 | $732,000 | -26.9% | 192,550 | +3.6% | 0.00% | 0.0% |
| Q1 2022 | $1,002,000 | -60.7% | 185,910 | -1.4% | 0.00% | -66.7% |
| Q4 2021 | $2,548,000 | +755.0% | 188,615 | +1036.2% | 0.00% | – |
| Q3 2021 | $298,000 | +0.7% | 16,600 | -3.7% | 0.00% | – |
| Q2 2021 | $296,000 | -39.6% | 17,245 | -29.6% | 0.00% | -100.0% |
| Q1 2021 | $490,000 | +19.2% | 24,488 | +1.4% | 0.00% | 0.0% |
| Q4 2020 | $411,000 | +2.5% | 24,138 | -0.2% | 0.00% | 0.0% |
| Q3 2020 | $401,000 | -29.3% | 24,178 | -1.2% | 0.00% | 0.0% |
| Q2 2020 | $567,000 | -73.9% | 24,468 | -79.9% | 0.00% | -80.0% |
| Q1 2020 | $2,173,000 | -12.1% | 121,718 | +6.2% | 0.01% | +25.0% |
| Q4 2019 | $2,473,000 | -9.5% | 114,588 | -23.7% | 0.00% | 0.0% |
| Q3 2019 | $2,734,000 | -49.3% | 150,138 | -1.0% | 0.00% | -50.0% |
| Q2 2019 | $5,397,000 | +5.0% | 151,688 | -0.8% | 0.01% | -11.1% |
| Q1 2019 | $5,140,000 | -11.2% | 152,988 | -13.2% | 0.01% | -10.0% |
| Q4 2018 | $5,791,000 | -44.3% | 176,172 | +3.2% | 0.01% | -33.3% |
| Q3 2018 | $10,404,000 | +25.2% | 170,668 | +0.3% | 0.02% | +25.0% |
| Q2 2018 | $8,308,000 | -54.8% | 170,149 | -1.6% | 0.01% | -57.1% |
| Q1 2018 | $18,376,000 | +18.9% | 172,937 | -33.1% | 0.03% | +33.3% |
| Q4 2017 | $15,449,000 | +147.4% | 258,683 | -0.6% | 0.02% | +133.3% |
| Q3 2017 | $6,244,000 | +20.4% | 260,183 | -1.9% | 0.01% | +12.5% |
| Q2 2017 | $5,184,000 | -15.8% | 265,153 | +1.1% | 0.01% | -20.0% |
| Q1 2017 | $6,155,000 | +93.4% | 262,243 | +1.1% | 0.01% | +100.0% |
| Q4 2016 | $3,182,000 | -23.2% | 259,353 | +7.6% | 0.01% | -28.6% |
| Q3 2016 | $4,142,000 | -11.4% | 241,103 | -26.6% | 0.01% | -12.5% |
| Q2 2016 | $4,676,000 | +5.3% | 328,613 | +1.7% | 0.01% | 0.0% |
| Q1 2016 | $4,441,000 | -14.4% | 322,973 | +4.9% | 0.01% | -11.1% |
| Q4 2015 | $5,188,000 | +57.6% | 307,873 | +2.5% | 0.01% | +50.0% |
| Q3 2015 | $3,291,000 | -10.4% | 300,273 | +2.2% | 0.01% | -14.3% |
| Q2 2015 | $3,674,000 | +2839.2% | 293,673 | +2482.2% | 0.01% | – |
| Q1 2015 | $125,000 | -97.1% | 11,373 | -95.9% | 0.00% | -100.0% |
| Q4 2014 | $4,265,000 | +25.7% | 275,173 | -2.1% | 0.01% | +33.3% |
| Q3 2014 | $3,394,000 | +90.6% | 281,173 | +102.3% | 0.01% | +100.0% |
| Q2 2014 | $1,781,000 | +615.3% | 138,958 | +575.4% | 0.00% | – |
| Q1 2014 | $249,000 | +58.6% | 20,573 | +48.3% | 0.00% | – |
| Q4 2013 | $157,000 | +1.9% | 13,873 | -6.1% | 0.00% | – |
| Q3 2013 | $154,000 | -8.3% | 14,773 | +1.4% | 0.00% | – |
| Q2 2013 | $168,000 | – | 14,573 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |